ABCL
AbCellera Biologics Inc.
Next earnings Aug 5, 2026 · consensus $-0.17 EPS, $8.01M rev
Last earnings +0.2% on 2026-05-11
$7.38
▲ +10.81%$7.38▲ +116.42%
over 1Y
L $2.78EODHDH $7.38
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+10.8%
1W+28.6%
1M+35.7%
3M+125.7%
YTD+115.2%
1Y+116.4%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Buy
Revenue grew 160.6% YoY; but unprofitable (net margin -194.9%).
AbCellera Biologics Inc. shows $75.1M in FY2025 revenue (+160.6% YoY), a -194.9% net margin, and -15.1% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $375M | $485M | $38.0M | $28.8M | $75.1M |
| Gross profit | — | — | — | — | — |
| Operating income | $204M | $217M | -$237M | -$315M | -$217M |
| Net income | $153M | $159M | -$146M | -$163M | -$146M |
| Diluted EPS | $0.48 | $0.50 | -$0.51 | -$0.55 | -$0.49 |
| Net margin | 40.9% | 32.7% | -385.0% | -564.8% | -194.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.11B
EV / EBITDA—
EV / Sales28.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-6.5%
FCF yield-7.8%
Quality & risk
ROIC (est.)-17.7%
Free cash flow-$174M
Total debt—
Net cash$129M
Altman Z-Score3.53 safe
Piotroski F-Score4/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+1.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-172026-06-17open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗8-KPeriod ending 2026-06-112026-06-12open ↗3Period ending 2026-06-012026-06-11open ↗8-KPeriod ending 2026-06-012026-06-05open ↗4Period ending 2026-06-032026-06-03open ↗4Period ending 2026-05-142026-05-18open ↗10-QPeriod ending 2026-03-312026-05-11open ↗8-KPeriod ending 2026-05-112026-05-11open ↗SCHEDULE 13G/AFiling2026-05-07open ↗
Frequently asked
- Is AbCellera Biologics Inc. (ABCL) a buy?
- ABCL currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 160.6% YoY; but unprofitable (net margin -194.9%).
- What is AbCellera Biologics Inc.'s quality score?
- ABCL scores 45.62745098039215/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001703057, latest 10-Q filed 2026-05-11) · EODHD · as of 6/26/2026, 5:49:58 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.